Malignant Ascites Clinical Trial
Official title:
A Phase II, Single-Arm, Open-Label, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Apatinib in Patients With Refractory Malignant Ascites
Malignant ascites is a severe complication of many types of human cancer. Animal and clinical analyses have shown that angiogenesis plays a critical role in the formation of malignant ascites. Therefore, drugs such as apatinib that target angiogenesis may control the development of malignant ascites. The study is to evaluate the efficacy and safety of apatinib in patients with refractory malignant ascites.
The study is to investigate the efficacy and safety of apatinib in patients with refractory malignant ascites. A total of 120 patients with performance status 0-2 were enrolled in this study and 500mg apatinib tablets were administered orally, once daily until disease progression or intolerable toxicity or patients withdrawal of consent. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06200376 -
A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT04051112 -
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites
|
Phase 1 | |
| Completed |
NCT00836654 -
Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05501340 -
PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03550560 -
EUS-Guided Drainage of Refractory Malignant Ascites
|
||
| Recruiting |
NCT04501744 -
A Study of M701 (EpCAM and CD3) in Malignant Ascites
|
Phase 1 | |
| Terminated |
NCT00028782 -
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
|
N/A | |
| Recruiting |
NCT05477927 -
Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases
|
Phase 1 | |
| Active, not recruiting |
NCT06266091 -
Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody
|
Phase 2 | |
| Withdrawn |
NCT04076566 -
Malignant Ascites Alfapump® Study
|
||
| Enrolling by invitation |
NCT01854866 -
Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion
|
Phase 2 | |
| Recruiting |
NCT03230708 -
Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites
|
Phase 1/Phase 2 | |
| Completed |
NCT01327235 -
Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites
|
Phase 2 | |
| Recruiting |
NCT06432296 -
Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody
|
Phase 3 | |
| Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
| Terminated |
NCT02496286 -
Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites
|
Phase 1 | |
| Completed |
NCT01532427 -
ALFApump System Post Marketing Surveillance Registry
|
||
| Completed |
NCT00326885 -
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
|
Phase 2 | |
| Recruiting |
NCT02530398 -
A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites
|
Phase 1 | |
| Withdrawn |
NCT00908219 -
A Study of Bevacizumab to Prevent Malignant Ascites
|
Phase 2 |